Charles Schwab Investment Management Inc Candel Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 46,777 shares of CADL stock, worth $420,993. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,777
Previous 46,777
-0.0%
Holding current value
$420,993
Previous $290,000
11.72%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CADL
# of Institutions
56Shares Held
6.41MCall Options Held
109KPut Options Held
130K-
Northpond Ventures, LLC1.94MShares$17.4 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA946KShares$8.52 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$7.41 Million0.0% of portfolio
-
State Street Corp Boston, MA492KShares$4.43 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA449KShares$4.04 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $260M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...